Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy
Thiazolidinediones (TZDs) are insulin sensitizers that decrease plasma glucose in type 2 diabetic patients. Thiazolidinediones can cause fluid retention and peripheral edema in diabetic patients, and the systematic fluid retention can be manifested as diabetic macular edema (DME). The overall goal of this study is to examine the effects of thiazolidinediones on the diabetic retinopathy and nephropathy.
This is a prospective, randomized, open-labeled, controlled design to assess the effects thiozolidinediones on the diabetic retinopathy and nephropathy. The investigators will recruit 300 type 2 diabetic patients without significant retinopathy, nephropathy and cardiovascular disease. Inclusion criteria are type 2 diabetes, age between 30-80 years old, with microabluminuria, no significant retinopathy, on submaximal dose of sulphonylureas and metformin treatment, and A1C between 7-9%. Exclusion criteria are on insulin treatment, significant retinopathy and significant nephropathy. Patients with cardiovascular diseases, malignancy, pregnancy, in acute intercurrent illness, congestive heart failure, myocardial infarction, received PCI or CABG. All subjects will receive EKG and CXR before randomization.
These subjects will be randomized equally to 3 groups: acarbose, rosiglitazone and pioglitazone. The investigators will follow up for 6 months to investigate the short-term effects and 5 years to evaluate the long-term outcomes. The primary study end point of short-term study will be the macular thickness changes measured by optical coherence tomography, the changes in the level of urinary albumin-to-creatinine ratio, circulating metabolic parameters and adipocytokines during thiozolidinediones treatment. Secondary end point will be fasting blood glucose, A1C levels, development of clinically significant macular edema, serum creatinine change in patients with no history of diabetic retinopathy and nephropathy at baseline.
The primary study end point of long-term study will be the development of clinically significant macular edema and the time from the base-line visit to the first detection of overt nephropathy. Secondary end points include the development of greater than moderate NPDR, the time to the first event of the time from the base-line visit to a doubling of the serum creatinine concentration, end-stage renal disease, or death.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy|
- Diabetic retinopathy [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]The macular thickness changes
- Diabetic nephropathy [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]The changes in the level of urinary albumin-to-creatinine ratio
- Diabetic retinopathy [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]Development of greater than moderate NPDR, clinically significant macular edema
- Diabetic nephropathy [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]The change of urine albumin excretion, estimated GFR change, progression to overt diabetic nephropathy.
|Study Start Date:||July 2010|
|Estimated Study Completion Date:||December 2015|
|Estimated Primary Completion Date:||December 2012 (Final data collection date for primary outcome measure)|
Actos 30 mg for 6 months
Drug: Actos (Pioglitazone)
Actos 30 mg for 6 months
Other Name: Pioglitazone
Active Comparator: Acarbose
Acarbose 50mg tid for 6 months
Acarbose 50 mg tid for 6 months
Other Name: Glucobay
Show Detailed Description
|Contact: Harn-Shen Chen, MD, PhDemail@example.com|
|Taipei Veterans General Hospital, Taiwan||Recruiting|
|Principal Investigator: Harn-Shen Chen, MD, PhD|
|Principal Investigator:||Harn-Shen Chen, MD, PhD||Taipei Veterans General Hospital, Taiwan|